EA
PTGX icon

Emerald Advisers’s Protagonist Therapeutics PTGX Stock Holding History

Emerald Advisers’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-103,850
Closed -$4.66M – 277
2021
Q2 		$4.66M Buy
+103,850
New +$3.43M 0.17% 121

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Emerald Advisers's PTGX Position: Q3 2021 in Review

Emerald Advisers sold out of Protagonist Therapeutics (PTGX) in Q3 2021, closing a stake of 103,850 shares — an estimated $4.66M sold.

Emerald Advisers first reported a position in PTGX in Q2 2021 and held it in 1 quarter. The position peaked at $4.66M in Q2 2021. 132 funds tracked by Wall St. Rank hold PTGX as of Q3 2021.

  • Emerald Advisers reported no remaining Protagonist Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Emerald Advisers sold 103,850 Protagonist Therapeutics shares in Q3 2021, an estimated $4.66M.
  • Emerald Advisers first reported a position in Protagonist Therapeutics in Q2 2021 and held it in 1 quarter.
  • Emerald Advisers's Protagonist Therapeutics position peaked at $4.66M in Q2 2021.
  • 132 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2021.

Based on Emerald Advisers's 13F filing for Q3 2021, filed 28 Oct 2021.